Published in Blood Weekly, February 19th, 2004
The U.S. market for all dosages of cytarabine for injection in liquid and lyophilized forms was approximately $6 million in 2002.
"We believe cytarabine injection in the liquid form is the most desirable as it requires less handling prior to administration," said Patrick Soon-Shiong, MD, APP chairman, president and chief executive officer. "Cytarabine injection is APP's first ANDA approval of 2004...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.